Form D · Other Health Care
Cyrano Therapeutics, Inc.
Washington, DC · CIK 0001832334
Offering snapshot reported Nov 16, 2020 · SEC filing
- Reported sold
- $4.08M Offering amount: $12.8M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 4, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2020 | Initial | $4,082,754 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-380646
Source: Form D, filed Nov 16, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerry Brunk | Director |
| Richard Geoffrion | Director, Executive |
| Robert Henkin | Director |
| Takahide Koda | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
5125 Macarthur Blvd. Nw, #20
Washington, DC, 20016
Washington, DC, 20016